Dangerous Drugs ActSection 28A
28A. Interpretation of Part IIA
In this Part –
“authorised patient” means a patient who is, pursuant to
section 28F, issued with a prescription to be treated with
medicinal cannabis;
“authorised pharmacist” means a Government pharmacist
who –
(a) has successfully completed a training course, as
approved by the Ministry, on the therapeutic use of
medicinal cannabis; and
(b) is authorised, in writing, by the Ministry to handle and
dispense medicinal cannabis;
“authorised specialist” means a specialist who –
(a) is registered as such under section 20 of the Medical
Council Act;
Acts 2022 535
(b) has successfully completed a training course, as
approved by the Ministry, on the therapeutic use of
medicinal cannabis; and
(c) is authorised, in writing, by the Ministry to make a
request for, and to issue a prescription to, a patient to
be treated with medicinal cannabis;
“specific therapeutic conditions” –
(a) means –
(i) spasticity, associated with multiple sclerosis, that
has failed to respond to conventional treatment;
(ii) severe refractory epilepsy that has failed
to respond to conventional anti-convulsant
treatment;
(iii) intractable nausea and vomiting, associated
with chemotherapy, that has failed to respond to
conventional anti-emetic treatment; or
(iv) severe intractable pain that has failed to respond
to conventional treatment; and
(b) includes such other therapeutic conditions as may be
authorised by the Medicinal Cannabis Therapeutic
Committee based on therapeutic evidence.